Polly A. Murphy, Director at Atea Pharmaceuticals, Inc. (AVIR), bought 6,100 shares at $4.17 ($25K) on 2025-05-18, disclosed to the SEC on 2026-05-20.
Open-market purchase of $25k AVIR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| AVIR | BUY | 2021-12-21 | $103K | — | Filing → |